The Research Working Group seeks to bridge the missing mile between basic research and the commercialization of products. Having an equal partnership between the Virtual Physiological Human Institute (VPH) and industries engaged in predictive medicine provides a unique opportunity to explore areas of mutual cooperation and benefit.

The key goals of this group are:

  • Promotion of in silico medicine in Horizon 2020;
  • Working towards the creation of a Public Private Partnership (PPP) on in silico medicine;
  • Creating links between the VPH Membership and Avicenna Industry Members


Priorities in 2018

→ Further develop a comprehensive position for Avicenna on what is needed in EU research;
→ Launch of the new Avicenna Alliance internship scheme;
→ A core focus of the VPH membership is on the FET Flagship on ageing and on shaping this Flagship programme;
→ Contribute to the three upcoming Avicenna Alliance White Papers

Working group leader:

  • Liesbet Geris
  • Executive Director, VPH Institute
  • Professor, University of Liège & KU Leuven (Belgium)

Avicenna Alliance news

In silico method mentioned in JRC report on alternatives to animal testing

On 7 February, the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) - which is an...

find out more ›

Artificial Intelligence and clinical research: which issues remain?

This issue is discussed in the new article written under the direction of Vincent Diebolt, Director of the French Clinical Research...

find out more ›

FEops  joins Avicenna Alliance

As further evidence of the Alliance’s growing momentum, Avicenna Alliance is happy to announce the newest addition to our list of members: FEops.

find out more ›

Show all activites